File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rapamycin attenuates liver graft injury in cirrhotic recipient - The significance of down-regulation of Rho-ROCK-VEGF pthway

TitleRapamycin attenuates liver graft injury in cirrhotic recipient - The significance of down-regulation of Rho-ROCK-VEGF pthway
Authors
KeywordsHepatic stellate cell (HSC)
Liver cirrhosis
Small-for-size graft
Issue Date2006
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
American Journal Of Transplantation, 2006, v. 6 n. 4, p. 697-704 How to Cite?
AbstractTo investigate whether rapamycin could attenuate hepatic I/R injury in a cirrhotic rat liver transplantation model, we applied a rat orthotopic liver transplantation model using 100% or 50% of liver grafts and cirrhotic recipients. Rapamycin was given (0.2 mg/kg, i.v.) at 30 min before graft harvesting in the donor and 24 h before operation, 30 min before total hepatectomy and immediately after reperfusion in the recipient. Rapamycin significantly improved small-for-size graft survival from 8.3% (1/12) to 66.7% (8/12) (p = 0.027). It also increased 7-day survival rates of whole grafts (58.3%[7/12] vs. 83.3%[10/12], p = 0.371). Activation of hepatic stellate cells was mainly found in small-for-size grafts during the first 7 days after liver transplantation. Rapamycin suppressed expression of smooth muscle actin, which is a marker of hepatic stellate cell activation, especially in small-for-size grafts. Intragraft protein expression and mRNA levels of vascular endothelial growth factor (VEGF) were down-regulated by rapamycin at 48 h both in whole and small-for-size grafts. Consistently, mRNA levels and protein expression of Rho and ROCK I were decreased by rapamycin during the 48 h after liver transplantation. In conclusion, rapamycin attenuated graft injury in a cirrhotic rat liver transplantation model by suppression of hepatic stellate cell activation, related to down-regulation of Rho-ROCK-VEGF pathway. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
Persistent Identifierhttp://hdl.handle.net/10722/83984
ISSN
2015 Impact Factor: 5.669
2015 SCImago Journal Rankings: 2.792
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMan, Ken_HK
dc.contributor.authorSu, Men_HK
dc.contributor.authorNg, KTen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorZhao, Yen_HK
dc.contributor.authorHo, JWen_HK
dc.contributor.authorSun, CKen_HK
dc.contributor.authorLee, TKen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:47:33Z-
dc.date.available2010-09-06T08:47:33Z-
dc.date.issued2006en_HK
dc.identifier.citationAmerican Journal Of Transplantation, 2006, v. 6 n. 4, p. 697-704en_HK
dc.identifier.issn1600-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83984-
dc.description.abstractTo investigate whether rapamycin could attenuate hepatic I/R injury in a cirrhotic rat liver transplantation model, we applied a rat orthotopic liver transplantation model using 100% or 50% of liver grafts and cirrhotic recipients. Rapamycin was given (0.2 mg/kg, i.v.) at 30 min before graft harvesting in the donor and 24 h before operation, 30 min before total hepatectomy and immediately after reperfusion in the recipient. Rapamycin significantly improved small-for-size graft survival from 8.3% (1/12) to 66.7% (8/12) (p = 0.027). It also increased 7-day survival rates of whole grafts (58.3%[7/12] vs. 83.3%[10/12], p = 0.371). Activation of hepatic stellate cells was mainly found in small-for-size grafts during the first 7 days after liver transplantation. Rapamycin suppressed expression of smooth muscle actin, which is a marker of hepatic stellate cell activation, especially in small-for-size grafts. Intragraft protein expression and mRNA levels of vascular endothelial growth factor (VEGF) were down-regulated by rapamycin at 48 h both in whole and small-for-size grafts. Consistently, mRNA levels and protein expression of Rho and ROCK I were decreased by rapamycin during the 48 h after liver transplantation. In conclusion, rapamycin attenuated graft injury in a cirrhotic rat liver transplantation model by suppression of hepatic stellate cell activation, related to down-regulation of Rho-ROCK-VEGF pathway. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.en_HK
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJTen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectHepatic stellate cell (HSC)en_HK
dc.subjectLiver cirrhosisen_HK
dc.subjectSmall-for-size graften_HK
dc.subject.meshGraft Survival - drug effects - genetics-
dc.subject.meshImmunosuppressive Agents - administration and dosage-
dc.subject.meshLiver Cirrhosis, Experimental - surgery-
dc.subject.meshLiver Transplantation-
dc.subject.meshSirolimus - administration and dosage-
dc.titleRapamycin attenuates liver graft injury in cirrhotic recipient - The significance of down-regulation of Rho-ROCK-VEGF pthwayen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1600-6135&volume=6&issue=4&spage=697&epage=704&date=2006&atitle=Rapamycin+attenuates+liver+graft+injury+in+cirrhotic+recipient+-+the+significance+of+down-regulation+of+Rho-ROCK-VEGF+pathwayen_HK
dc.identifier.emailMan, K: kwanman@hku.hken_HK
dc.identifier.emailNg, KT: ledodes@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailLee, TK: tkwlee@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityNg, KT=rp01720en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityLee, TK=rp00447en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-6143.2005.01231.xen_HK
dc.identifier.pmid16539626-
dc.identifier.scopuseid_2-s2.0-33644755913en_HK
dc.identifier.hkuros126123en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644755913&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue4en_HK
dc.identifier.spage697en_HK
dc.identifier.epage704en_HK
dc.identifier.isiWOS:000235839900009-
dc.publisher.placeDenmarken_HK
dc.identifier.scopusauthoridMan, K=7101754072en_HK
dc.identifier.scopusauthoridSu, M=36878070800en_HK
dc.identifier.scopusauthoridNg, KT=7403178513en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridZhao, Y=7407402718en_HK
dc.identifier.scopusauthoridHo, JW=7402649982en_HK
dc.identifier.scopusauthoridSun, CK=7404248685en_HK
dc.identifier.scopusauthoridLee, TK=7501439435en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.citeulike543107-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats